Annual report pursuant to Section 13 and 15(d)

Schedule of Sale of Business (Details)

v3.24.1
Schedule of Sale of Business (Details) - Interpace Pharma Solutions [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Purchase price $ 7,000
Earnout received 1,043
Working capital adjustment, net (117) (766)
Less: transaction costs (307)
Total net consideration (117) 6,970
Assets and liabilities disposed of, net [1] (6,970)
Gain (loss) on sale $ (117)
[1] includes goodwill and intangible assets written down prior to the Transaction. The goodwill write-down was approximately $8.4 million and the write-down of intangible assets was approximately $3.8 million.